Concord Biotech Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 25	Mar ' 24	Mar ' 23

Sources of funds

Owner's fund

Equity share capital

10.46

10.46

10.46

Share application money

-

-

-

Preference share capital

-

-

-

Reserves & surplus

1,802.18

1,514.79

1,281.52

Loan funds

Secured loans

0.38

6.23

31.24

Unsecured loans

-

-

-

Total

1,813.03

1,531.48

1,323.22

Uses of funds

Fixed assets

Gross block

1,083.36

813.77

781.39

Less : revaluation reserve

-

-

-

Less : accumulated depreciation

288.67

238.46

188.41

Net block

794.69

575.32

592.98

Capital work-in-progress

50.66

211.48

172.70

Investments

335.20

244.37

137.72

Net current assets

Current assets, loans & advances

853.64

668.15

611.25

Less : current liabilities & provisions

221.15

167.83

191.43

Total net current assets

632.49

500.32

419.82

Miscellaneous expenses not written

-

-

-

Total

1,813.03

1,531.48

1,323.22

Notes:

Book value of unquoted investments

1.40

0.67

0.67

Market value of quoted investments

333.80

243.70

137.05

Contingent liabilities

26.67

26.75

26.59

Number of equity sharesoutstanding (Lacs)

1046.16

1046.16

1046.16